Did you know that prostate cancer spreads to the bone in 9 out of 10 men with metastatic castration-resistant prostate cancer (mCRPC)? One of the reasons it may have spread is because the cancer is no longer responding to hormonal or surgical treatment that lowers testosterone.
Among the treatment options being utilized, there is a treatment called Xofigo® (radium Ra 223 dichloride) injection. Xofigo is used to treat prostate cancer that no longer responds to hormonal or surgical treatment that lowers testosterone. It is for men whose prostate cancer has spread to the bone with symptoms but not to other parts of the body.
Xofigo contains the radioactive material radium 223, which works by going to areas in the bones that are growing quickly, just like calcium does. Bone metastases are one of those rapidly growing areas. Once at the metastases, Xofigo gives off a strong energy that travels a short distance. The energy is deadly to the cancer cells in the bones but does limited damage to nearby healthy cells. Xofigo can be absorbed by other organs, primarily the bone marrow and digestive system, which may result in side effects in those healthy tissues.
Contact us at 310.264.9000 to speak to one of our radiologists about mCRPC, risk factors, symptoms and treatments like Xofigo that may be appropriate for certain patients.
You can also get more information regarding Xofigo on their website: https://www.xofigo-us.com